Form 6-K NOVARTIS AG For: Dec 31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated
February 4, 2026
(Commission File No. 1-15024)
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
Form 20-F: x
|
Form 40-F: o
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Novartis AG
|
|||
|
Date:
February 4, 2026
|
By:
|
/s/ PAUL PENEPENT
|
|
|
Name:
|
Paul Penepent
|
||
|
Title:
|
Head Financial Reporting and Accounting
|
||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis ends mid-stage trial for Fabhalta in lupus nephritis
- Terraton Issues First Carbon Removal Credits from Agricultural Waste, Signs Agreements with Climeworks Solutions, Climate Impact Partners, Carbonfuture, CUR8, and Terraset
- EasyAgentIDX Launches IDX Platform With Developer API and AI Connections for Real Estate Websites
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share